Search Orphan Drug Designations and Approvals
-
Generic Name: | cyclosporine | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Verkazia | ||||||||||||||||
Date Designated: | 05/04/2007 | ||||||||||||||||
Orphan Designation: | Treatment of vernal keratoconjunctivitis | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Harrow Eye, LLC 102 Woodmont Blvd Ste 610 Nashville, Tennessee 37205-2221 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | cyclosporine |
---|---|---|
Trade Name: | Verkazia | |
Marketing Approval Date: | 06/23/2021 | |
Approved Labeled Indication: | Treatment of vernal keratoconjunctivitis (VKC) in children and adults | |
Exclusivity End Date: | 06/23/2028 | |
Exclusivity Protected Indication* : | Treatment of vernal keratoconjunctivitis (VKC) in children and adults | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-